{"id":16,"date":"2026-02-23T05:00:39","date_gmt":"2026-02-23T05:00:39","guid":{"rendered":"https:\/\/biopharmapathways.com\/?page_id=16"},"modified":"2026-02-25T00:01:11","modified_gmt":"2026-02-25T00:01:11","slug":"biopharma-pathways","status":"publish","type":"page","link":"https:\/\/biopharmapathways.com\/?page_id=16","title":{"rendered":"Biopharma Pathways"},"content":{"rendered":"

<\/p>\n

\n
<\/div>\n
\n

Illuminating the Path to Breakthrough Therapies<\/h2>\n

Guiding life-science innovators through the complexities of drug\u2011product development with clarity, strategy, and expert partnership management.<\/p>\n<\/p>\n<\/div>\n<\/header>\n

<\/p>\n

\n

Our Mission<\/h2>\n

\n Biopharma Pathways empowers life\u2011science teams to navigate the scientific, operational, and partnership demands of bringing new therapies to patients. We provide clear, actionable guidance across development and collaboration landscapes, helping innovators remove barriers, move with confidence, and advance work that truly matters.\n <\/p>\n<\/section>\n

<\/p>\n

\n

What We Do<\/h2>\n

\n Biopharma Pathways was founded to strengthen the foundations of early drug\u2011product programs by bringing structure, insight, and momentum to complex development efforts. Drawing on deep experience in technical planning, CDMO oversight, and cross\u2011functional leadership, we help teams align around the right priorities, make informed decisions, and keep programs moving steadily toward the next milestone.\n <\/p>\n

\n
\n

Technical Development Strategy<\/h3>\n

Provide guidance across CMC aspects, including formulation, analytical strategy, and risk\u2011based planning to support every phase of drug\u2011product development.<\/p>\n<\/p>\n<\/div>\n

\n

Regulatory Strategy<\/h3>\n

Deliver forward\u2011looking strategies aligning technical decisions with regulatory expectations\u2014reducing development risk while enabling more efficient, successful submissions and advancement through key milestones.<\/p>\n<\/p>\n<\/div>\n

\n

CDMO & Partner Management<\/h3>\n

Provide strategic and operational support to manage CDMOs and partner organizations effectively\u2014improving communication, timelines, and program alignment.<\/p>\n<\/p>\n<\/div>\n

\n

Due Diligence & Asset Evaluation<\/h3>\n

Deliver independent, science\u2011grounded due diligence to support investment and in\u2011licensing decisions. We evaluate technical feasibility, development readiness, CMC strength, and regulatory considerations to give investors and BD teams a clear, unbiased view of risk, maturity, and value.<\/p>\n<\/p>\n<\/div>\n<\/div>\n<\/section>\n

<\/p>\n

\n

Who We Are<\/h2>\n

\n Christina Vessely, PhD, has over 25 years of experience in analytical and formulation development within the biotechnology industry. Her experience ranges from early-stage research and development for small and start-up firms through late-stage development and commercialization for mid-sized and large pharmaceutical companies. She has been involved in priority review and fast-track programs and has participated in Pre-approval inspections (PAI) and PAI-enabling activities, such as design and execution of validation studies and evaluation of GMP systems. She has also authored and edited analytical sections for multiple filings in the U.S. and EU (IND\/IMPD, BLA\/MAA).\n

\nIn the analytical arena, Christina\u2019s areas of expertise have included analytical method development and validation, development of reference standards and other critical reagents, stability strategy and evaluation, and establishment of comparability and\/or similarity. Her product experience includes vaccines, insulin analogs, cytokines, monoclonal antibodies, ADC\u2019s, and other therapeutic proteins. She also has extensive experience with drug\/device combination products. She has been involved in the development and execution of CMC\/Regulatory strategy for both novel and biosimilar products.\n<\/p>\n


\n Learn more about our experience
\n <\/a>
\n<\/section>\n

<\/p>\n

\n

Our Approach<\/h2>\n